|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenues | |||||
| Product revenue, net | |||||
| Collaboration revenue | |||||
| Total revenues | |||||
| Expenses | |||||
| Cost of product revenue | |||||
| Cost of collaboration revenue | |||||
| Research and development | |||||
| Selling, general, and administrative | |||||
| Gain on sale of intellectual property | |||||
| Loss from operations | |||||
| Interest income | |||||
| Interest expenses | |||||
| Foreign currency gains (losses) | |||||
| Other income, net | |||||
| Loss before income tax and share of loss from equity method investment | |||||
| Loss before income tax | |||||
| Income tax benefit | |||||
| Share of loss from equity method investment | |||||
| Net loss | |||||
| Loss per share — basic (in dollars per share) | |||||
| Total loss per share — basic (in dollars per share) | |||||
| Loss per share — diluted (in dollars per share) | |||||
| Total loss per share — diluted (in dollars per share) | |||||
| Weighted-average shares used in calculating net loss per ordinary share — basic (in shares) | |||||
| Total weighted-average shares used in calculating net loss per ordinary share — basic (in shares) | |||||
| Weighted-average shares used in calculating net loss per ordinary share —diluted (in shares) | |||||
| Total weighted-average shares used in calculating net loss per ordinary share —diluted (in shares) | |||||
Loading...